FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096156910> ?p ?o ?g. }

• W2096156910 endingPage "1151" @default.
• W2096156910 startingPage "1139" @default.
• W2096156910 abstract "Chronic pain is a leading cause of disability and represents a relevant societal burden. Opioids are widely used for managing chronic non-cancer pain; however, the high incidence of side effects is often the main reason for discontinuation. Two formulations have recently been studied to improve the tolerability of opioids (tapentadol extended release [ER] and oxycodone/naloxone ER), but a direct comparison between these drugs is not available in the literature. The comparative cost effectiveness of these two drugs has not previously been assessed. The objective of this meta-analysis is a clinical and economic evaluation of tapentadol ER and oxycodone/naloxone ER for the treatment of musculoskeletal pain, by indirect comparison with controlled release (CR) oxycodone.A structured literature review was conducted to identify published data for the health-economic model. The authors performed a meta-analysis on three selected randomized controlled trials (RCTs) for each treatment (tapentadol ER and oxycodone/naloxone ER). As measure of treatment effect, risk ratio was calculated, compared to the control active treatment (CR oxycodone), for the following outcomes: discontinuation rate due to adverse events, due to gastrointestinal (GE) side effects and central nervous system (CNS) side effects. A Markov model was developed to compare the cost effectiveness of tapentadol ER and oxycodone/naloxone ER. Four health states were defined: (1) patients still on treatment; (2) occurrence of adverse events (gastroenterology, central nervous system); (3) treatment discontinuation as consequence of ineffectiveness of treatment; and (4) treatment discontinuation as consequence of adverse events.Both drugs showed a significant clinical advantage over the active control, CR oxycodone; however, tapentadol ER resulted in a better risk ratio reduction for the primary outcome of discontinuation rate due to adverse events and for the secondary outcome nausea and vomiting. The two drugs gave equivalent results in the capacity of reduction of constipation risk. In the economic evaluation both interventions were cost effective compared with CR oxycodone. However, tapentadol ER showed the most favorable results as in 65% of cases it was less costly and produced a considerable quality adjusted life years (QALY) gain. The higher impact of tapentadol ER on the cost effectiveness results was probably due to the price and the lower incidence of adverse events and related discontinuation rate, resulting in a further economic advantage.Both tapentadol ER and oxycodone/naloxone ER are cost effective interventions compared with CR oxycodone; however, tapentadol ER was shown to provide better clinical outcomes at lower costs." @default.
• W2096156910 created "2016-06-24" @default.
• W2096156910 creator A5003585738 @default.
• W2096156910 creator A5013747199 @default.
• W2096156910 date "2014-03-03" @default.
• W2096156910 modified "2023-10-13" @default.
• W2096156910 title "Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain" @default.
• W2096156910 cites W1562338169 @default.
• W2096156910 cites W1945672276 @default.
• W2096156910 cites W1964663021 @default.
• W2096156910 cites W1979997745 @default.
• W2096156910 cites W1980190867 @default.
• W2096156910 cites W1982417601 @default.
• W2096156910 cites W1991790545 @default.
• W2096156910 cites W2003069609 @default.
• W2096156910 cites W2009058749 @default.
• W2096156910 cites W2012637353 @default.
• W2096156910 cites W2052897638 @default.
• W2096156910 cites W2111608210 @default.
• W2096156910 cites W2119436730 @default.
• W2096156910 cites W2122756722 @default.
• W2096156910 cites W2124990868 @default.
• W2096156910 cites W2127305375 @default.
• W2096156910 cites W2128848460 @default.
• W2096156910 cites W2129787366 @default.
• W2096156910 cites W2137956198 @default.
• W2096156910 cites W2138446311 @default.
• W2096156910 cites W2144693398 @default.
• W2096156910 cites W2149012794 @default.
• W2096156910 cites W2158521628 @default.
• W2096156910 cites W2163255559 @default.
• W2096156910 cites W2167613032 @default.
• W2096156910 cites W2169043109 @default.
• W2096156910 doi "https://doi.org/10.1185/03007995.2014.894501" @default.
• W2096156910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24528146" @default.
• W2096156910 hasPublicationYear "2014" @default.
• W2096156910 type Work @default.
• W2096156910 sameAs 2096156910 @default.
• W2096156910 citedByCount "32" @default.
• W2096156910 countsByYear W20961569102014 @default.
• W2096156910 countsByYear W20961569102015 @default.
• W2096156910 countsByYear W20961569102016 @default.
• W2096156910 countsByYear W20961569102017 @default.
• W2096156910 countsByYear W20961569102018 @default.
• W2096156910 countsByYear W20961569102019 @default.
• W2096156910 countsByYear W20961569102021 @default.
• W2096156910 countsByYear W20961569102022 @default.
• W2096156910 countsByYear W20961569102023 @default.
• W2096156910 crossrefType "journal-article" @default.
• W2096156910 hasAuthorship W2096156910A5003585738 @default.
• W2096156910 hasAuthorship W2096156910A5013747199 @default.
• W2096156910 hasConcept C126322002 @default.
• W2096156910 hasConcept C168563851 @default.
• W2096156910 hasConcept C170493617 @default.
• W2096156910 hasConcept C197934379 @default.
• W2096156910 hasConcept C2776029756 @default.
• W2096156910 hasConcept C2778375690 @default.
• W2096156910 hasConcept C2778715236 @default.
• W2096156910 hasConcept C2778750930 @default.
• W2096156910 hasConcept C2779777798 @default.
• W2096156910 hasConcept C2780505013 @default.
• W2096156910 hasConcept C2780820201 @default.
• W2096156910 hasConcept C2781063702 @default.
• W2096156910 hasConcept C42219234 @default.
• W2096156910 hasConcept C71924100 @default.
• W2096156910 hasConcept C98274493 @default.
• W2096156910 hasConceptScore W2096156910C126322002 @default.
• W2096156910 hasConceptScore W2096156910C168563851 @default.
• W2096156910 hasConceptScore W2096156910C170493617 @default.
• W2096156910 hasConceptScore W2096156910C197934379 @default.
• W2096156910 hasConceptScore W2096156910C2776029756 @default.
• W2096156910 hasConceptScore W2096156910C2778375690 @default.
• W2096156910 hasConceptScore W2096156910C2778715236 @default.
• W2096156910 hasConceptScore W2096156910C2778750930 @default.
• W2096156910 hasConceptScore W2096156910C2779777798 @default.
• W2096156910 hasConceptScore W2096156910C2780505013 @default.
• W2096156910 hasConceptScore W2096156910C2780820201 @default.
• W2096156910 hasConceptScore W2096156910C2781063702 @default.
• W2096156910 hasConceptScore W2096156910C42219234 @default.
• W2096156910 hasConceptScore W2096156910C71924100 @default.
• W2096156910 hasConceptScore W2096156910C98274493 @default.
• W2096156910 hasIssue "6" @default.
• W2096156910 hasLocation W20961569101 @default.
• W2096156910 hasLocation W20961569102 @default.
• W2096156910 hasOpenAccess W2096156910 @default.
• W2096156910 hasPrimaryLocation W20961569101 @default.
• W2096156910 hasRelatedWork W1977210133 @default.
• W2096156910 hasRelatedWork W1995188972 @default.
• W2096156910 hasRelatedWork W2016375172 @default.
• W2096156910 hasRelatedWork W2297721326 @default.
• W2096156910 hasRelatedWork W2419144289 @default.
• W2096156910 hasRelatedWork W2696352493 @default.
• W2096156910 hasRelatedWork W2950902187 @default.
• W2096156910 hasRelatedWork W3091420358 @default.
• W2096156910 hasRelatedWork W4318671286 @default.
• W2096156910 hasRelatedWork W4386913490 @default.
• W2096156910 hasVolume "30" @default.
• W2096156910 isParatext "false" @default.

• next